Latiglutenase

Drug Profile

Latiglutenase

Alternative Names: ALV-003; IMGX-003

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Stanford University
  • Developer Alvine Pharmaceuticals
  • Class Cysteine endopeptidases; Recombinant proteins
  • Mechanism of Action Cysteine endopeptidase stimulants; Prolyl endopeptidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coeliac disease

Most Recent Events

  • 15 Mar 2016 ImmunogenX acquires latiglutenase from Alvine Pharmaceuticals
  • 28 Aug 2015 Phase-II development is ongoing in Canada, Finland, Ireland, Norway, USA and United Kingdom
  • 26 Aug 2013 Phase-II clinical trials in Coeliac disease in USA (PO) (NCT01917630)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top